GGrantIndex
Sort

17,828 grants matching crispr

The Function of Small RNA-Based viral Defense System in E. coli - Renewal 1

$339,591
Ekaterina Semenova · Rutgers, The State Univ Of N.J. · R01 · FY2023 · GM

The Function of Small RNA-Based viral Defense System in E. coli - Renewal 1

$339,591
Konstantin V Severinov · Rutgers, The State Univ Of N.J. · R01 · FY2022 · GM

The Function of Small RNA-Based viral Defense System in E. coli - Renewal 1

$339,591
Ekaterina Semenova · Rutgers, The State Univ Of N.J. · R01 · FY2024 · GM

Complex Mechanisms of Mutation and Mutation Avoidance in Living Cells

$339,555
Eric Alan Josephs · University Of North Carolina Greensboro · R35 · FY2020 · GM

Molecular and Cellular Biology Core

$339,474
Philip Ross Hardwidge · Kansas State University · P20 · FY2024 · GM

CRISPR/Cas9-Based Gene Editing for the Correction of Duchenne Muscular Dystrophy

$339,448
Charles A Gersbach · Duke University · R01 · FY2017 · AR

CRISPR/Cas9-Based Gene Editing for the Correction of Duchenne Muscular Dystrophy

$339,430
Charles A Gersbach · Duke University · R01 · FY2018 · AR

CRISPR/Cas9-Based Gene Editing for the Correction of Duchenne Muscular Dystrophy

$339,411
Charles A Gersbach · Duke University · R01 · FY2019 · AR

CRISPR/Cas9-Based Gene Editing for the Correction of Duchenne Muscular Dystrophy

$339,393
Charles A Gersbach · Duke University · R01 · FY2020 · AR

Project 2: Regulation of Rotavirus Host Range, Neutralization, and M cell Interactions in Enteric Biomimetics

$339,385
Harry Bernard Greenberg · Stanford University · U19 · FY2025 · AI

Multiscale modeling of an inductive hair follicle microenvironment in engineered skin substitute

$339,316
Yuhang Zhang · University Of Cincinnati · R01 · FY2023 · AR

Development of a high throughput functional genomics platform to interrogate gene function in 3-dimensional in vitro models

$339,188
Madhu Lal · National Center For Advancing Translational Sciences · ZIA · FY2018 · TR

Uncovering the mechanism and role of a widespread anti-CRISPR-Cas9 protein

$339,150
Joseph Bondy-Denomy · University Of California, San Francisco · R01 · FY2021 · GM

Uncovering the mechanism and role of a widespread anti-CRISPR-Cas9 protein

$339,150
Joseph Bondy-Denomy · University Of California, San Francisco · R01 · FY2022 · GM

Regenerative Therapies for Inherited Blood Disorders-Gene therapy

$339,113
Andre Larochelle · National Heart, Lung, And Blood Institute · ZIA · FY2017 · HL

Mechanisms of Prion Aggregation and Species Barriers

$339,063
Christina Sigurdson · University Of California, San Diego · R01 · FY2016 · NS

Mechanisms of Prion Aggregation and Species Barriers

$339,063
Christina Sigurdson · University Of California, San Diego · R01 · FY2018 · NS

Mechanisms of Prion Aggregation and Species Barriers

$339,063
Christina Sigurdson · University Of California, San Diego · R01 · FY2020 · NS

Mechanisms of Prion Aggregation and Species Barriers

$339,063
Christina Sigurdson · University Of California, San Diego · R01 · FY2017 · NS

Mechanisms of Prion Aggregation and Species Barriers

$339,063
Christina Sigurdson · University Of California, San Diego · R01 · FY2019 · NS

Epigenetic Control of Nephron Progenitor Cell Lifespan

$339,027
Samir S El-Dahr · Tulane University Of Louisiana · R01 · FY2019 · DK

Combining dynamics of ligand presentation with dynamics of hESC response in colonies with defined architecture

$339,000
Eric D. Siggia · Rockefeller University · R01 · FY2018 · GM

Combining dynamics of ligand presentation with dynamics of hESC response in colonies with defined architecture

$339,000
Eric D. Siggia · Rockefeller University · R01 · FY2019 · GM

Structural and Functional Characterization of RNA polymerase and its Regulators from Mycobacterium tuberculosis and Clostridioides difficile

$339,000
Elizabeth A Campbell · Rockefeller University · R01 · FY2020 · GM

Structural and Functional Characterization of RNA polymerase and its Regulators from Mycobacterium tuberculosis and Clostridioides difficile

$339,000
Elizabeth A Campbell · Rockefeller University · R01 · FY2023 · GM